Zimmer’s stock receives “buy” rating from Canaccord Genuity: 5 points

Canaccord Genuity has given Zimmer’s stock a “buy” rating, according to a Dakota Financial News report.

Advertisement

Here are five points:

 

1. Canaccord Genuity currently has a $150 price target on the stock.

 

2. The company also has a consensus rating of “buy” from other equities research analysts.

 

3. Zimmer Holdings has a 52-week low of $94.73 and a 52-week high of $121.84.

 

4. The stock’s 50-day moving average is $113 and its 200-day moving average is $115.

 

5. The company has a market cap of $19.32 billion.

 

More articles on devices:
Russell indexes add InVivo Therapeutics — 5 key notes
Former OtisMed CEO gets 2 years in prison in knee device scandal — 5 key notes
Amedica shares shoot up 10% — 6 key notes

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.